Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

HealthLynked (HLYK) EBITDA Margin (2016 - 2025)

HealthLynked (HLYK) has disclosed EBITDA Margin for 10 consecutive years, with 184.41% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 9413.0% to 184.41% in Q3 2025 year-over-year; TTM through Sep 2025 was 126.19%, a 2207.0% increase, with the full-year FY2024 number at 151.66%, down 8127.0% from a year prior.
  • EBITDA Margin was 184.41% for Q3 2025 at HealthLynked, down from 110.67% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 10.19% in Q3 2021 to a low of 3746.7% in Q4 2022.
  • A 5-year average of 300.37% and a median of 110.67% in 2025 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -367284bps in 2022, then surged 363063bps in 2023.
  • HealthLynked's EBITDA Margin stood at 73.86% in 2021, then crashed by -4973bps to 3746.7% in 2022, then skyrocketed by 97bps to 116.08% in 2023, then decreased by 0bps to 116.38% in 2024, then tumbled by -58bps to 184.41% in 2025.
  • Per Business Quant, the three most recent readings for HLYK's EBITDA Margin are 184.41% (Q3 2025), 110.67% (Q2 2025), and 116.68% (Q1 2025).